The Fridley, Minn.-based medtech giant is touting InPen as the first and only FDA-cleared smart insulin pen on the market for people on multiple daily insulin injections. The system is designed to provide real-time glucose readings alongside insulin dose information without switching apps.
Medtronic obtained the InPen technology in its acquisition of Companion Medical in September. The InPen adds to Medtronic’s diabetes portfolio of the MiniMed insulin pump, Guardian CGM and more.
“We’re pleased to build on the success of InPen with added real-time glucose data which provides a complete picture for users as they look to give themselves the right dose of insulin at the right time,” said Sean Salmon, EVP and president of the diabetes business at Medtronic, in a news release. “Our successful integration of these devices in just two months following the close of our Companion Medical acquisition is a testament to the close collaboration of our employees and strong passion to serve our customers with better solutions to manage their diabetes.”
The InPen app will continue to display information from other currently compatible CGM systems on a three-hour delay, the company said.